Join Lisa Larkin, MD, FACP, IF, MSCP, and Maryam Lustberg, MD, MPH, for a case-based, evidence-informed discussion addressing one of the most challenging questions in OncoMenopause care: menopausal hormone therapy (MHT) in breast cancer survivors.

This session centers on real clinical cases—the nuanced scenarios healthcare providers face when survivors ask about MHT. Drs. Larkin and Lustberg will walk through risk assessment, interpretation of evolving evidence, and shared decision-making frameworks, highlighting where guidelines may be unclear and how to navigate those gray areas thoughtfully.

Designed for OncoMenopause healthcare providers, this conversation offers practical insight, clinical nuance, and actionable strategies to support individualized, patient-centered care in an evolving survivorship landscape.

Lisa Larkin, MD, FACP, IF, MSCP, is a nationally recognized women’s health internist and the founder of HERmedicine. With decades of clinical experience, Dr. Larkin has seen firsthand how gaps in evidence-based education impact both patients and clinicians. In addition to leading HERmedicine, she is the founder of Ms.Medicine and a longstanding advocate for advancing women’s healthcare. Her work is driven by a commitment to expanding access to reliable, comprehensive information and improving the quality of care delivered to women everywhere.

Maryam Lustberg, MD, MPH, is a breast medical oncologist and currently serves as Chief of Breast Oncology and Director of the Breast Center at Yale Cancer Center in New Haven, Connecticut. She is the co-chair of Symptom Intervention for the USA National Cancer Institute Alliance Clinical Trials and the immediate Past President of MASCC, an international organization devoted to improving cancer supportive care worldwide. Her research focuses on biomarkers of therapeutic response and toxicity, as well as on cancer treatment symptom management and survivorship care optimization.